Lenacapavir posts 100% HIV prevention in PURPOSE 1

Lenacapavir for HIV treatment: Gilead achieves 100 percent HIV prevention in late-stage PURPOSE trial

Gilead's lenacapavir posted 100% efficacy in the Phase 3 PURPOSE 1 trial for HIV prevention in cisgender women. The result strengthens the case for lenacapavir PrEP and raises the stakes for Gilead's next regulatory and clinical catalysts.

IntelligenceRegulatory Impact▾

FDA decisions frame this story. Regulatory relevance is high for HIV, with lenacapavir and Truvada most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

• The Phase 3 PURPOSE 1 trial demonstrated 100% efficacy for twice-yearly injectable lenacapavir in preventing HIV-1 infection in cisgender women.
• Yeztugo (lenacapavir sodium) is FDA-approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg, offering a differentiated long-acting injectable option against oral alternatives.
• A Phase 3 trial investigating lenacapavir as a once-yearly injection for HIV PrEP is currently recruiting, signaling continued development momentum beyond the twice-yearly formulation.
• In a second pivotal study, lenacapavir reduced HIV infections by 96% and demonstrated superiority to Truvada, establishing a clinical case for switching from daily oral regimens.

IntelligenceCompetitive Intelligence▾

Gilead Sciences are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.

The Development

Gilead Sciences has secured a major clinical win for its HIV prevention portfolio. The Phase 3 PURPOSE 1 trial demonstrated 100% efficacy for twice-yearly injectable lenacapavir in preventing HIV-1 infection in cisgender women, delivering a perfect prevention profile in a key population segment at risk for sexually acquired HIV-1.

This result arrives alongside a complementary clinical dataset. In a second pivotal study, lenacapavir reduced HIV infections by 96% and demonstrated superiority to Truvada, the long-standing oral combination of emtricitabine and tenofovir disoproxil fumarate used for HIV prevention in adults at high risk.

The clinical evidence underpins an already-approved regulatory status. Yeztugo (lenacapavir sodium) is FDA-approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to starting the drug.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for HIV. Expect implications for pricing, access, and launch sequencing.

How does Yeztugo compare to current PrEP options?

Truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.

Yeztugo's twice-yearly injectable schedule represents a departure from the oral PrEP paradigm. The twice-yearly dosing frequency distinguishes lenacapavir from daily oral alternatives, though any future label expansions—such as additional age groups, weight categories, or indications—would require separate regulatory actions.

IntelligenceStrategic Takeaways▾

The Phase 3 PURPOSE 1 trial demonstrated 100% efficacy for twice-yearly injectable lenacapavir in preventing HIV-1 infection in cisgender women. Yeztugo (lenacapavir sodium) is FDA-approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg , offering a differentiated long-acting injectable option against oral alternatives. A Phase 3 tri

What does the clinical evidence show?

The PURPOSE 1 readout is the headline catalyst. The Phase 3 PURPOSE 1 trial demonstrated 100% efficacy for twice-yearly injectable lenacapavir in preventing HIV-1 infection in cisgender women. Zero infections occurred in the lenacapavir arm, establishing an exceptional prevention profile in this population.

That finding sits within a broader clinical picture. A second pivotal study showed lenacapavir reduced HIV infections by 96% and demonstrated superiority to Truvada. The two-study dataset positions lenacapavir as a clinically differentiated option in the HIV prevention space, particularly for patients seeking to avoid daily oral medication.

Development continues beyond the current approval. A Phase 3 trial is investigating lenacapavir as a once-yearly injection for HIV pre-exposure prophylaxis, which would further reduce dosing frequency if successful.

IntelligenceEvidence Quality▾

Grounded in 2 regulatory sources and 2 peer-reviewed sources.

Treatment Landscape

Lenacapavir operates in a landscape where oral PrEP remains the standard of care. Truvada, the combination of emtricitabine and tenofovir disoproxil fumarate, is indicated for pre-exposure prophylaxis in adults at high risk.

The clinical case for lenacapavir rests on practical differences: dosing frequency (twice yearly versus daily) and prevention efficacy (100% in PURPOSE 1; 96% in the second pivotal study). Whether these benefits translate into clinical adoption depends on implementation factors—such as provider training, patient access, and real-world tolerability—that the current evidence does not address.

Investor Implications

A 100% prevention efficacy result in a Phase 3 trial establishes lenacapavir as a clinically differentiated asset within HIV prevention. The next value-inflection points for investors are: (1) recruiting and outcomes data from the Phase 3 trial investigating once-yearly lenacapavir for HIV PrEP; (2) real-world implementation signals from an active implementation study of lenacapavir PrEP for HIV prevention; and (3) any regulatory actions tied to label expansion, additional populations, or formulation changes. The PURPOSE 1 data itself does not quantify market size, adoption rates, or revenue forecasts, so BD teams should treat the clinical readout as a catalyst for further due diligence rather than as a complete commercial case.

Frequently Asked Questions

Related profiles

• Gilead Sciences
• lenacapavir
• TRUVADA

Related coverage

• Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials
• Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial
• FDA approves Keytruda adjuvant NSCLC use in early-stage lung cancer